Latest News

Tiziana Life Sciences Interview to Air on Bloomberg International on the RedChip Money Report

10 July 2020

NEW YORK and LONDON, July 10, 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a clinical stage biotechnology company developing targeted drugs for cancer, inflammatory diseases and COVID-19, today announced an interview with...

Read more

Total Voting Rights and StemPrintER demerger update

01 July 2020

London, New York, 1 July 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the "Company" or "Tiziana"), a US and UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease...

Read more

Agreement with STC Biologics for GMP Manufacturing of an anti-Interleukin-6-Receptor Monoclonal Antibody for Clinical Studies in Patients with COVID-19.

29 June 2020

Tiziana Life Sciences Announces Agreement with STC Biologics for GMP Manufacturing of an anti-Interleukin-6-Receptor Monoclonal Antibody for Clinical Studies in Patients with COVID-19.

Read more

Annual General Meeting

23 June 2020

London, New York, 23 June 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the "Company" or "Tiziana"), a US and UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease...

Read more

Exercise of Warrants and Issue of Equity and Total Voting Rights

22 June 2020

London, New York, 22 June 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the "Company" or "Tiziana"), a US and UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease...

Read more

Patent Granted for Oral Administration

19 June 2020

Tiziana has been granted the first-ever Patent on a Transformational Technology for Oral Delivery of all Anti-CD3 Monoclonal Antibodies for the treatment of Human Diseases First-ever granted patent on oral administration of anti-CD3 monoclonal antibodies for immunotherapies Transformational oral formulation technologies applicable to other antibodies

Read more

Page 1 of 15 Next